c-MET (Y1230S)

MET · Variant type: point · HGVS: p.Y1230S

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Cabozantinib	95.5%	4.5%	92.73
2	Gilteritinib	90.7%	9.3%	88.97
3	Tivozanib	72.9%	27.1%	92.42
4	Pacritinib	69.2%	30.8%	88.64
5	Repotrectinib	60.3%	39.7%	84.21
6	Defactinib	56.1%	43.9%	92.68
7	Lenvatinib	47.6%	52.4%	97.74
8	Dacomitinib	42.8%	57.2%	97.99
9	Neratinib	39.4%	60.6%	93.18
10	Selpercatinib	38.4%	61.6%	96.72
11	Canertinib	37.8%	62.2%	96.49
12	Fedratinib	34.2%	65.8%	96.21
13	Sunitinib	33.7%	66.3%	91.73
14	Fostamatinib	31.1%	68.9%	96.74
15	Entrectinib	20.7%	79.3%	93.69
16	Abemaciclib	19.1%	80.9%	91.48
17	Osimertinib	19.0%	81.0%	97.24
18	Imatinib	17.1%	82.9%	99.00
19	Brigatinib	16.7%	83.3%	82.96
20	Dabrafenib	15.5%	84.5%	94.74
21	Vandetanib	14.0%	86.0%	95.74
22	Tepotinib	13.7%	86.3%	99.75
23	Quizartinib	12.9%	87.1%	99.50
24	Capmatinib	12.8%	87.2%	99.75
25	Leniolisib	10.5%	89.5%	100.00

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Cabozantinib	95.5%	—	—
Gilteritinib	90.7%	—	—
Tivozanib	72.9%	—	—
Pacritinib	69.2%	—	—
Repotrectinib	60.3%	—	—
Defactinib	56.1%	—	—
Lenvatinib	47.6%	—	—
Dacomitinib	42.8%	—	—
Neratinib	39.4%	—	—
Selpercatinib	38.4%	—	—
Canertinib	37.8%	—	—
Fedratinib	34.2%	—	—
Sunitinib	33.7%	—	—
Fostamatinib	31.1%	—	—
Entrectinib	20.7%	—	—
Abemaciclib	19.1%	—	—
Osimertinib	19.0%	—	—
Imatinib	17.1%	—	—
Brigatinib	16.7%	—	—
Dabrafenib	15.5%	—	—
Vandetanib	14.0%	—	—
Tepotinib	13.7%	—	—
Quizartinib	12.9%	—	—
Capmatinib	12.8%	—	—
Leniolisib	10.5%	—	—

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 13.3ms